News
AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which ...
AstraZeneca has signed a research agreement worth more than $5 billion with Chinese drugmaker CSPC Pharmaceutical Group, the ...
The deal with China’s CSPC Pharmaceuticals, focused on AI-driven research, aims to advance the discovery and development of ...
AstraZeneca (NASDAQ:AZN) is one of the 8 Best Inexpensive Stocks to Buy Right Now. On June 9, the first patient was dosed by ...
5don MSN
Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.
2d
GlobalData on MSNAstraZeneca taps Chinese biotech in $5.2bn chronic disease research dealAstraZeneca has joined the long list of big pharma companies enlisting the services of Chinese biotechs, signing a deal worth ...
Explore more
CSPC will use its artificial-intelligence-driven, dual-engine efficient drug discovery platform to analyze the binding ...
The collaboration will focus on identifying pre-clinical candidates for high-priority targets, including a small molecule ...
Friday’s deal with fits neatly within AstraZeneca’s business development strategy of upping investments in AI and in China.
Cambridge: AstraZeneca has entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group ...
British drugmaker AstraZeneca unveiled on Friday an AI-assisted research partnership with Chinese counterpart CSPC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results